Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00523848 · FLOW

Participant flow

Bortezomib, Doxorubicin Hydrochloride Liposome, and Thalidomide as First-line Therapy in Treating Patients With Previously Untreated Stage I, II, or III Multiple Myeloma · Source last updated 2017-02-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Patients receive low-dose oral thalidomide once a day on days 1-28, bortezomib IV on days 1, 4, 15, and 18, and doxorubicin hydrochloride liposome IV over 60-90 minutes on days 1 and 15. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
    id
    FG000
    title
    Arm 1 - VDT: VELCADE, Doxil and Low-dose Thalidomide
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        11
      type
      Adverse Event
    2. reasons
      1. group Id
        FG000
        num Subjects
        2
      type
      Withdrawal by Subject
    3. reasons
      1. group Id
        FG000
        num Subjects
        2
      type
      NOT TREATED (Became ineligible)
    4. reasons
      1. group Id
        FG000
        num Subjects
        5
      type
      Disease Progression
    5. reasons
      1. group Id
        FG000
        num Subjects
        4
      type
      Other, unspecified
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        46
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        44
      type
      Treated With Study Therapy
    3. achievements
      1. group Id
        FG000
        num Subjects
        22
      type
      COMPLETED
    4. achievements
      1. group Id
        FG000
        num Subjects
        24
      type
      NOT COMPLETED
    title
    Overall Study
Complete source fields
groups
  1. description
    Patients receive low-dose oral thalidomide once a day on days 1-28, bortezomib IV on days 1, 4, 15, and 18, and doxorubicin hydrochloride liposome IV over 60-90 minutes on days 1 and 15. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
    id
    FG000
    title
    Arm 1 - VDT: VELCADE, Doxil and Low-dose Thalidomide
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        11
      type
      Adverse Event
    2. reasons
      1. group Id
        FG000
        num Subjects
        2
      type
      Withdrawal by Subject
    3. reasons
      1. group Id
        FG000
        num Subjects
        2
      type
      NOT TREATED (Became ineligible)
    4. reasons
      1. group Id
        FG000
        num Subjects
        5
      type
      Disease Progression
    5. reasons
      1. group Id
        FG000
        num Subjects
        4
      type
      Other, unspecified
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        46
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        44
      type
      Treated With Study Therapy
    3. achievements
      1. group Id
        FG000
        num Subjects
        22
      type
      COMPLETED
    4. achievements
      1. group Id
        FG000
        num Subjects
        24
      type
      NOT COMPLETED
    title
    Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice